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Relationship between “a body shape 
index (ABSI)” and body composition in obese 
patients with type 2 diabetes
Fernando Gomez‑Peralta1*, Cristina Abreu1, Margarita Cruz‑Bravo1, Elvira Alcarria1, Gala Gutierrez‑Buey1, 
Nir Y. Krakauer2 and Jesse C. Krakauer3
Abstract 
Background: Obesity is known to be related to the development of type 2 diabetes mellitus (T2D). The most com‑
monly used anthropometric indicator (body mass index [BMI]) presents several limitations such as the lack of possibil‑
ity to distinguish adipose tissue distribution. Thus, this study examines the suitability of a body shape index (ABSI) for 
prediction of body composition and sarcopenic obesity in obese or overweight T2D subjects.
Methods: Cross‑sectional study in 199 overweight/obese T2D adults. Anthropometric (BMI, ABSI) and body composi‑
tion (fat mass [FM], fat‑free mass [FFM], fat mass index [FMI] and fat‑free mass index, and the ratio FM/FFM as an index 
of sarcopenic obesity) data was collected, as well as metabolic parameters (glycated haemoglobin  [HbA1c], mean 
blood glucose, fasting plasma glucose [FPG], high‑density‑lipoprotein cholesterol [HDL], low‑density‑lipoprotein 
cholesterol, total cholesterol, and triglycerides [TG] levels; the ratio TG/HDL was also calculated as a surrogate marker 
for insulin resistance).
Results: ABSI was significantly associated with age and waist circumference. It showed a statistically significant corre‑
lation with BMI exclusively in women. Regarding body composition, in men, ABSI was associated with FM (%), while in 
women it was associated with both FM and FFM. Both males and females groups with high ABSI scores were signifi‑
cantly older (men: 59.3 ± 10.8 vs 54.6 ± 10.1, p ≤ 0.05; women: 65.1 ± 9.8 vs 58.1 ± 13.3, p ≤ 0.005) and showed lower 
FFM values (men: 62.3 ± 9.0 vs 66.2 ± 9.3, p ≤ 0.05; women: 48.7 ± 5.6 vs 54.5 ± 8.9, p ≤ 0.001) compared with low‑ABSI 
groups. Multiple linear regression revealed that ABSI independently predict FMI and the FM/FFM ratio in women. Sar‑
copenic obesity was identified in 70 (36.5%) individuals according to the FM/FFM ratio. The AUROC of ABSI was 63.1% 
(95% CI 54.6–71.6%; p = 0.003) and an ABSI value of 0.083 m11/6 kg−2/3 was the optimal threshold in discriminating 
patients with sarcopenic obesity (sensitivity: 48%, specificity: 73%). Moreover, a significant association between ABSI 
and FPG was found in men.
Conclusions: ABSI could be useful to identify visceral and sarcopenic obesity in overweight/obese adults with T2D, 
adding some relevant clinical information to traditional anthropometric measures.
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Background
According to the global trends, the prevalence of diabe-
tes mellitus is expected to increase considerably [1, 2]. 
Obesity, and especially visceral obesity, is known to be 
related to the development of type 2 diabetes (T2D), and 
cardiovascular diseases (CVD) [3, 4], through the release 
of fatty acids and inflammatory cytokines into the portal 
bloodstream [5].
Some anthropometric measurements considered sur-
rogates for visceral obesity have long been used in medi-
cal settings for obesity-associated health risk evaluation. 
A commonly used measure is the body mass index (BMI). 
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However, it does not serve to distinguish between mus-
cle and fat accumulation and gives no indication of body 
shape [6]. An increase in BMI could be attributed to an 
increase in either fat mass (FM), fat-free mass (FFM) or 
both, limiting the utility of BMI to estimate adiposity [7, 
8].
Waist circumference (WC) is widely seen as a measure 
of central adiposity. Its association with insulin resistance 
has been reported to be better than that of BMI [9–11]. 
Related indexes, such as waist-height ratio (WHtR), 
waist-hip ratio (WHR), and roundness index have been 
extensively studied. However, WC and WC-derived 
measures (i.e. WHtR) are highly correlated with BMI 
[12], limiting, their utility beyond BMI [13]. To overcome 
the limitations of the existing anthropometric measures 
to efficiently estimate both visceral abdominal and gen-
eral adiposities and predict mortality.
Krakauer et al. [14] developed a new composite anthro-
pometric measure. A body shape index (ABSI), based on 
normalizing WC to BMI and height. The advantage of 
ABSI is that it combines information from WC, height 
and weight. A high ABSI indicates that WC is higher than 
expected for a given height and weight, and corresponds 
to a more central concentration of body mass. ABSI pre-
dicts mortality independently from BMI [15, 16]. Of note, 
the DECODE study group found a positive linear rela-
tionship of all-cause CVD mortality with ABSI, whereas 
BMI, WC, and WHR showed J-shaped associations [17].
Additionally, ageing is usually associated with an 
increase in FM coexisting with a decrease in FFM, lead-
ing to sarcopenia [18]. Sarcopenia is characterized by 
degenerative loss of skeletal muscle mass and strength 
and correlates with physical disability [19]. In the case of 
sarcopenic obesity [20], ABSI may be useful, in addition 
to the traditional anthropometric measures.
The association of ABSI and body composition meas-
urements has been reported in a geriatric study [21]. 
Overweight/obese subjects with no significant clinically 
comorbidities [22], and Japanese subjects with T2D [23] 
have also been studied. The methodology and the results 
differed between studies, but overall, they pointed out a 
positive relationship between ABSI and visceral and sar-
copenic obesity.
Here we assess ABSI in an observational study of 
Caucasian obese or overweight subjects with T2D. Our 
findings suggest that ABSI is associated with body com-
position and sarcopenic obesity.
Methods
Design and study subjects
This cross-sectional observational study was carried out 
at the Hospital General de Segovia (Segovia, Spain) in 
accordance with the Declaration of Helsinki, including 
all amendments, and was approved by the correspond-
ing Independent Research Ethics Committee. All par-
ticipants provided written informed consent to use their 
data.
The study population comprised consecutive Caucasian 
overweight/obese (BMI ≥ 25  kg/m2) adult subjects with 
T2D. A glomerular filtration rate over 60 ml per minute 
per 1.73 m2 of body surface area (modification of diet in 
renal disease [MDRD] formula [24]) and normal creati-
nine levels were used to exclude clinically relevant renal 
impairment. Additional criteria for inclusion were not 
taking pioglitazone, GLP-1 receptor agonists or SGLT2 
inhibitors, and performance of the studies required for 
this analysis.
Measurements
Anthropometric parameters
Height (m) and weight (kg) were measured according to 
standard methods, and the BMI was then calculated as 
weight/height squared (kg/m2). Waist circumference (WC) 
was measured at the uppermost border of the iliac crests 
in standing positions with a non-stretchable tape (cm). 
ABSI was calculated as WC/(BMI2/3 * height1/2), expressed 
in  m11/6  kg−2/3. Men and women were each divided into 
two groups by using the median of individual ABSI meas-
urements as the threshold value. Subjects with ABSI lower 
than the median values were assigned to the “lower-ABSI” 
group and subjects with greater ABSI than the median 
value were assigned to the “higher-ABSI” group.
Body composition measurements
Fat mass (FM) and fat-free mass (FFM) were clinically 
determined by bioelectrical impedance analysis and cal-
culated through the software supplied by the manufac-
turers and expressed in kg [25]. These measurements 
were performed in the morning, after an overnight fast. 
Subjects were asked to refrain from a strenuous exercise 
from the night before and to void the bladder before the 
examination. Fat mass index (FMI) and fat-free mass 
index (FFMI) were then calculated as FM (kg) and FFM 
(kg) divided by the squared height in meters  (m2), respec-
tively. The ratio between FM and FFM (FM/FFM) was 
calculated as an index of sarcopenic obesity. As per Prado 
et  al. [26] we used the following cut-off values for FM/
FFM ratio: < 0.40 for metabolic healthy obese individu-
als in whom the increase in FM relatively low compared 
to FFM; FM/FFM ratios between 0.40 and 0.80 for obese 
individuals; and FM/FFM > 0.80 for sarcopenic obese 
subjects, in whom FM predominates FFM.
Metabolic parameters
The collection of metabolic parameters included glycated 
haemoglobin (HbA1c), mean blood glucose (MBG), 
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fasting plasma glucose (FPG), high-density lipoprotein 
cholesterol (HDL), low-density lipoprotein cholesterol 
(LDL), total cholesterol (TC), and triglycerides (TG) lev-
els. The ratio between TG and HDL (TG/HDL) was also 
calculated as a surrogate marker for insulin resistance, as 
is suggested by Cordero et al. [19].
Statistical considerations
To control for the well-known sexual dimorphism in body 
composition, all analyses were stratified by gender. Values 
were expressed as mean ± standard deviation (SD) for 
quantitative variables and as number and percentages for 
categorical variables. The Student’s t test or the Mann–
Whitney U test for quantitative variables and the Fisher’s 
exact test or the Chi square test for qualitative variables 
were used to compare mean values between groups. Cor-
relation analyses between anthropometric measures and 
body composition and metabolic parameters were evalu-
ated with Pearson’s/Spearman correlation analysis. To 
determine if ABSI and BMI were independently associ-
ated with FM, FFM, FMI, FFMI, FM/FFM ratio, and TG/
HDL index, linear regression analyses were performed. 
Correlations between anthropometric parameters and 
body composition measurements were adjusted for age, 
due to the documented relationship between the ageing 
process and changes in body composition, often without 
concomitant changes in body weight or BMI [20]. The 
area under the ROC curve (AUROC) was determined 
to compare the ability of ABSI and BMI to discriminate 
between patients with and without sarcopenic obesity. 
The significance level was set at p < 0.05 and all statisti-
cal analyses were carried out with the statistical package 
for the Social Sciences (SPSS) v.22.0 (SPSS, Inc., Chicago, 
IL).
Results
Between March 2012 and April 2016, we identified 203 
subjects who met the initial selection criteria; of these, 
four subjects were excluded due to screening failures 
(n = 2) and incomplete data (n = 2). Thus, the evaluable 
population comprised 199 subjects (100 women and 99 
men), whose characteristics are shown in Table 1.
According to the FM/FFM ratio, 70 (36.5%) subjects 
had sarcopenic obesity, as defined by an FM/FFM ratio 
> 0.8. Only 9 of the male subjects showed sarcopenic 
obesity.
Pearson correlations between different variables are 
shown in Table 2 either adjusted or raw values. In both 
sexes, WC positively correlated with all body composition 
measurements. ABSI was significantly associated with age 
(men, r = 0.438, p = 0.000; women, r = 0.220, p = 0.029) 
and WC (men, r = 0.577, p = 0.000; women, r = 0.417, 
p = 0.000), and achieved a significant association with 
BMI only in women (r = -0.301, p = 0.003). Correlations 
between BMI and the body composition parameters 
were statistically significant for both men and women 
across all measures. Correlations between ABSI and 
body composition measurements in men were not sig-
nificant except for the percentage of FM (r = −  0.302, 
p = 0.003), while in women ABSI significantly correlated 
with FM (r = −  0.236, p = 0.022) and FFM (r = −  0.270, 
p = 0.008). Overall, correlations between BMI and ABSI 
with metabolic parameters were not significant for either 
men or women (data not tabulated), except for the sig-
nificant association found between ABSI and FPG in men 
(r = −  0.379, p = 0.000), and between BMI and TG in 
women (r = − 0.224, p = 0.043).
The ROC curves of ABSI and BMI for predicting sar-
copenia are shown in Fig. 1. Additionally, the AUROC of 
ABSI is shown in Fig.  1 and had a value of 63.1% (95% 
CI 54.6–71.6%; p = 0.003). We estimated a cut-off value 
of ABSI with potential clinical utility. In our analysis, the 
optimal threshold for the ABSI value in discriminating 
patients was 0.083  m11/6  kg−2/3 (sensitivity: 48%, speci-
ficity: 73%). For BMI, the cut-off value was 37,45 kg/m2, 
with sensitivity of 81% and specificity of 77%.
To selectively analyse the association between ABSI 
and anthropometric measures describing adiposity and 
sarcopenia independently from BMI, men and women 
were divided into two groups by using the median of 
individual ABSI measurements as the threshold value 
(0.0834 m11/6 kg−2/3). Higher-ABSI men had a mean WC 
significantly greater than the lower-ABSI men group 
(121.8 ± 13.6 vs 114.9 ± 19.4  cm, p ≤ 0.05). The higher-
ABSI male and female groups were significantly older 
(age in years men: 59.3 ± 10.8 vs 54.6 ± 10.1, p ≤ 0.05; 
women: 65.1 ± 9.8 vs 58.1 ± 13.3, p ≤ 0.005). With higher-
ABSI vs. lower-ABSI FFM was lower (men: 62.3 ± 9.0 vs 
66.2 ± 9.3  kg, p ≤ 0.05; women: 48.7 ± 5.6 vs 54.5 ± 8.9, 
p ≤ 0.001), demonstrating the ability of ABSI to identify 
sarcopenia. Among women, BMI, FM, FMI, FFM, and 
FFMI exhibited significantly greater values in the lower-
ABSI group than the higher-ABSI group (Table 3).
Multiple linear regression analyses revealed that BMI 
independently predicted all body composition param-
eters both in men and women. ABSI, however, inde-
pendently predicted FMI and FM/FFM ratio in women 
(Additional file 1: Table S1).
Discussion
This study utilizes indexes defining body composition 
that are easily obtained in routine clinical practice. It 
assesses the relationship between the components of 
body composition and abdominal fat surrogate markers 
in a retrospective Spanish cohort overweight or obese 
adults with T2D.
Page 4 of 8Gomez‑Peralta et al. Diabetol Metab Syndr  (2018) 10:21 
In our series, we found that BMI was highly and posi-
tively correlated with all parameters of body composi-
tion (i.e. FM, FFM, FMI, etc.), in both males and females. 
The observed lack of correlation between ABSI and BMI 
in the general population was confirmed in the male 
cohort, while there was a modest correlation in the 
female cohort. This is in line with the recent study con-
ducted by Hardy et al. [27] that aimed to determine the 
best anthropometric discriminators of T2D among white 
and black subjects in a large cohort. It was concluded 
that those anthropometric measures that included WC 
(such as WHR) were the strongest discriminators of T2D 
across race-gender groups, while BMI was a compara-
ble discriminator to WC among males, but not in female 
subjects.
ABSI was positively correlated with WC both in males 
and females. A higher ABSI-value is an indication of a 
higher abdominal fat deposition [14] that leads to sys-
temic inflammation [28], insulin resistance [29], and 
accompanies a systemic loss of skeletal muscle mass, as 
reported previously [30]. In our study, the association 
of ABSI with body composition parameters differed by 
Table 1 Baseline characteristics
Data are expressed as mean ± standard deviation, unless otherwise indicated
ABSI A body shape index, BMI body mass index, FM fat mass, FFM free‑fat mass, FMI fat mass index, FFMI free‑fat mass index, FM/FFM ratio fat mass‑free‑fat mass, FPG 
fasting plasma glucose, HbA1c haemoglobin A1c, HDL high‑density lipoprotein cholesterol, LDL low‑density lipoprotein cholesterol, MBG mean blood glucose, TC total 
cholesterol, TG Triglycerides, WC Waist circumference
a MDRD formula [25]
Men
n = 99
Women
n = 100
p value
Age (years) 57.0 ± 10.7 61.5 ± 12.2 0.004
Duration of type 2 diabetes (years) 11.0 ± 6.9 12.9 ± 8.3 0.247
Height (cm) 167.9 ± 7.2 154.8 ± 7.0 < 0.001
Weight (kg) 102.7 ± 20.0 95.1 ± 19.3 0.007
BMI (kg/m2) 36.4 ± 6.5 39.7 ± 6.9 < 0.001
WC (cm) 118.3 ± 17.0 117.8 ± 14.9 0.791
ABSI  (m11/6 kg−2/3) 0.0827 ± 0.0081 0.0810 ± 0.0072 0.001
Body fat (%) 36.7 ± 8.9 45.3 ± 5.2 < 0.001
FM (kg) 37.5 ± 15.5 44.0 ± 12.7 < 0.001
FFM (kg) 64.5 ± 9.4 51.4 ± 7.9 < 0.001
FMI 13.3 ± 5.5 18.3 ± 4.8 < 0.001
FFMI 22.8 ± 2.6 21.5 ± 2.9 < 0.001
FM/FFM ratio 0.59 ± 0.26 0.85 ± 0.16 < 0.001
 < 0.4, n (%) 11 (11.5) 0 (0.0) < 0.001
 ≥ 0.4 and ≤ 0.8, n (%) 76 (79.2) 35 (36.5)
 > 0.8, n (%) 9 (9.4) 61 (63.5)
HbA1c (%) 8.4 ± 1.3 8.3 ± 1.7 0.109
MBG (mg/dL) 194.8 ± 38.5 190.5 ± 48.9 0.033
FPG (mg/dL) 182.0 ± 50.2 172.1 ± 73.0 0.109
HDL (mg/dL) 38.8 ± 11.7 44.8 ± 8.9 < 0.001
LDL (mg/dL) 99.8 ± 30.2 112.6 ± 40.6 0.060
TG (mg/dl) 202.7 ± 225.1 199.9 ± 182.6 0.246
TC (mg/dL) 176.1 ± 35.0 194.7 ± 57.7 0.003
TG/HDL 6.3 ± 9.5 4.7 ± 5.1 0.440
 ≤ 1.8, n (%) 7 (9.5) 7 (10.1) > 0.999
 > 1.8, n (%) 67 (90.5) 62 (89.9)
Creatinine (mg/dL) 1.0 ± 0.2 0.8 ± 0.2 < 0.001
Glomerular filtration rate (mL/min/1.73 m2)a 91.5 ± 20.8 79.8 ± 18.9 < 0.001
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gender: ABSI was negatively associated with the percent-
age of FM (p = 0.000) in the male cohort, while it was 
negatively associated with both FM (p = 0.022) and FFM 
(p = 0.008) in the female cohort. This discrepancy in the 
findings between men and women could be explained 
by the differences in body fat distribution [31]. In men, 
adipose tissue tends to be more centrally deposited, sug-
gesting that WC would be sensitive to FM, whereas in 
women adipose tissue is mainly deposited in the lower 
body (gluteal-femoral), indicating that WC may be less 
sensitive to FM [32].
The higher-ABSI females and males showed signifi-
cantly lower FFM than the lower-ABSI groups, with com-
parable BMI in men and lower BMI in women. These 
findings could support the hypothesis that abdominal 
fat deposition may be associated with a loss of skeletal 
muscle mass in some subjects, i.e. sarcopenic obesity. 
Obesity-related sarcopenia, is a syndrome of progressive 
and generalised loss of skeletal muscle mass and function, 
characterized by a higher FM in relation to FFM [26]. 
Our study indicates that ABSI may not be just a marker 
of visceral obesity, but may also represent an index of 
decreased muscle mass (i.e. sarcopenia) in T2D subjects, 
which is congruent with the positive correlation of ABSI 
and age generally reported and also found in our sample.
The AUROC analysis supports that ABSI showed abil-
ity for predicting the presence of sarcopenic obesity (the 
lower bound of the 95% CI of AUC is greater than 0.5; 
[33]). Even though the ability of BMI to discriminate 
between patients with and without sarcopenic obesity is 
higher than for ABSI, as indicated by the respective sen-
sitivity and specificity values, ABSI could add relevant 
Table 2 Pearson’s rank correlation for body mass compositions measurements in men and women
The upper‑right triangle of the table shows correlations of the raw values, while the lower‑left triangle shows correlations adjusted for age
ap = 0.000; bp = 0.001; cp = 0.016; dp = 0.003; ep = 0.010; fp = 0.011; gp = 0.002; hp = 0.028; ip = 0.039; jp = 0.008; kp = 0.029; lp = 0.021; mp = 0.005; np = 0.022; 
op = 0.017; pp = 0.007; qp = 0.030; rp = 0.004; sp = 0.031; tp = 0.041
ABSI A body shape index, BMI body mass index, % FM Percentage of fat mass, FM fat mass, FMI fat mass index, FFM Fat‑free mass, FFMI Fat‑free mass index, FM/FFM 
ratio between fat mass and fat‑free mass, WC waist circumference
WC % FM BMI Age ABSI FM FFM FMI FFMI FM/FFM
Men
 WC 1 0.260f 0.693a 0.136 0.577a 0.833a 0.376a 0.827a 0.499a 0.668a
 % FM 0.322g 1 0.697a − 0.313g − 0.395a 0.892a − 0.106 0.916a − 0.069 0.932a
 BMI 0.730a 0.691a 1 − 0.156 − 0.164 0.885a 0.389a 0.908a 0.553a 0.736a
 Age – – – 1 0.438a − 0.225h − 0.153 − 0.162 0.071 − 0.179
 ABSI 0.580a − 0.302d − 0.107 – 1 − 0.124 − 0.164 − 0.092 − 0.023 − 0.061
 FM 0.895a 0.888a 0.883a – − 0.030 1 0.211i 0.975a 0.175 0.923a
 FFM 0.406a − 0.164 0.374a – − 0.110 0.184 1 0.081 0.794a ‑0.158
 FMI 0.869a 0.924a 0.906a – − 0.023 0.976a 0.058 1 0.173 0.945a
 FFMI 0.495a − 0.049 0.573a – − 0.060 0.196 0.816a 0.188 1 − 0.135
 FM/FFM 0.711a 0.938a 0.729a – 0.020 0.921a − 0.190 0.944a − 0.124 1
Women
 WC 1 0.548a 0.722a − 0.017 0.417a 0.827a 0.571a 0.849a 0.556a 0.696a
 % FM 0.551a 1 0.631a − 0.123 − 0.115 0.812a 0.323b 0.822a 0.225h 0.945a
 BMI 0.723a 0.628a 1 − 0.087 − 0.301d 0.856a 0.742a 0.907a 0.794a 0.680a
 Age – – – 1 0.220k − 0.236 l − 0.280m − 0.110 − 0.029 − 0.110
 ABSI 0.431a − 0.091 − 0.291r – 1 − 0.236n − 0.270j − 0.182 − 0.196 − 0.097
 FM 0.847a 0.812a 0.863a – − 0.194 1 0.764a 0.944a 0.582a 0.856a
 FFM 0.590a 0.303d 0.750a – − 0.222s 0.748a 1 0.657a 0.794a 0.335b
 FMI 0.852a 0.820a 0.906a – − 0.163 0.950a 0.656a 1 0.684a 0.869a
 FFMI 0.556a 0.224q 0.795a – − 0.194 0.593a 0.819a 0.685a 1 0.243o
 FM/FFM 0.699a 0.944a 0.677a – − 0.075 0.859a 0.318g 0.867a 0.241t 1
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information about abdominal obesity, body composition 
and mortality risk. In fact, our proposed ABSI cut-off 
point diagnostic of sarcopenic obesity (0.083 m11/6 kg−2/3) 
exactly agreed with the finding of a previous study [14], 
where ABSI above the same threshold predicted a higher 
mortality relative hazard.
The data presented add to the emerging, growing body 
of literature regarding different aspects of ABSI. A recent 
longitudinal study conducted with Australian adults 
showed a positive association between ABSI and mortal-
ity, suggesting that this measure could be a useful pre-
dictor of mortality hazard in different populations [34]. 
In this context, further studies are needed to investigate 
whether ABSI could be used as an indicator of the effec-
tiveness of lifestyle modifications in T2D subjects.
The authors recognise some limitations in the study 
that should be considered when interpreting the results. 
First of all, this is an observational study with a cross-
sectional design; therefore, there is no patient follow-up, 
which would be of importance to elucidate the correla-
tion between body composition and ABSI; besides, we 
cannot rule out that some degree of bias may have been 
introduced. Secondly, as this study was performed at a 
single centre, findings in other centres may be different 
and, certainly, further confirmation is needed. Nonethe-
less, all these findings should guide further prospective 
studies with some broader samples [34].
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Fig. 1 ROC curve for ABSI to discriminate between patients with and without sarcopenic obesity
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In conclusion, ABSI identifies visceral obesity and sar-
copenia in overweight or obese subjects with T2D, add-
ing some relevant clinical information to traditional 
anthropometric measures.
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